Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 127

1.

Mitochondrial and metabolic-based protective strategies in Huntington's disease: the case of creatine and coenzyme Q.

Naia L, Ribeiro MJ, Rego AC.

Rev Neurosci. 2011 Dec 2;23(1):13-28. doi: 10.1515/RNS.2011.060. Review.

PMID:
22150069
[PubMed - indexed for MEDLINE]
2.

Huntington's disease: the current state of research with peripheral tissues.

Sassone J, Colciago C, Cislaghi G, Silani V, Ciammola A.

Exp Neurol. 2009 Oct;219(2):385-97. doi: 10.1016/j.expneurol.2009.05.012. Epub 2009 May 19. Review.

PMID:
19460373
[PubMed - indexed for MEDLINE]
3.

Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.

Yang L, Calingasan NY, Wille EJ, Cormier K, Smith K, Ferrante RJ, Beal MF.

J Neurochem. 2009 Jun;109(5):1427-39. doi: 10.1111/j.1471-4159.2009.06074.x. Epub 2009 Mar 28.

PMID:
19476553
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Mitochondrial-associated metabolic changes and neurodegeneration in Huntington's disease - from clinical features to the bench.

Rosenstock TR, Duarte AI, Rego AC.

Curr Drug Targets. 2010 Oct;11(10):1218-36. Review.

PMID:
20840066
[PubMed - indexed for MEDLINE]
5.

Mitochondrial structural and functional dynamics in Huntington's disease.

Reddy PH, Mao P, Manczak M.

Brain Res Rev. 2009 Jun;61(1):33-48. doi: 10.1016/j.brainresrev.2009.04.001. Epub 2009 Apr 24. Review.

PMID:
19394359
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Emerging chemotherapeutic strategies for Huntington's disease.

Ryu H, Ferrante RJ.

Expert Opin Emerg Drugs. 2005 May;10(2):345-63. Review.

PMID:
15934871
[PubMed - indexed for MEDLINE]
7.

Evidence of oxidant damage in Huntington's disease: translational strategies using antioxidants.

Stack EC, Matson WR, Ferrante RJ.

Ann N Y Acad Sci. 2008 Dec;1147:79-92. doi: 10.1196/annals.1427.008. Review.

PMID:
19076433
[PubMed - indexed for MEDLINE]
8.

The therapeutic role of creatine in Huntington's disease.

Ryu H, Rosas HD, Hersch SM, Ferrante RJ.

Pharmacol Ther. 2005 Nov;108(2):193-207. Epub 2005 Aug 1. Review.

PMID:
16055197
[PubMed - indexed for MEDLINE]
9.

Mitochondria in Huntington's disease.

Damiano M, Galvan L, Déglon N, Brouillet E.

Biochim Biophys Acta. 2010 Jan;1802(1):52-61. doi: 10.1016/j.bbadis.2009.07.012. Epub 2009 Aug 11. Review.

PMID:
19682570
[PubMed - indexed for MEDLINE]
Free Article
10.

Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.

Hansson O, Castilho RF, Korhonen L, Lindholm D, Bates GP, Brundin P.

J Neurochem. 2001 Aug;78(4):694-703.

PMID:
11520890
[PubMed - indexed for MEDLINE]
11.

Targeting cellular energy production in neurological disorders.

Baker SK, Tarnopolsky MA.

Expert Opin Investig Drugs. 2003 Oct;12(10):1655-79. Review.

PMID:
14519086
[PubMed - indexed for MEDLINE]
12.

Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.

Reddy PH, Charles V, Williams M, Miller G, Whetsell WO Jr, Tagle DA.

Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):1035-45.

PMID:
10434303
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Bioenergetics in Huntington's disease.

Grünewald T, Beal MF.

Ann N Y Acad Sci. 1999;893:203-13. Review.

PMID:
10672239
[PubMed - indexed for MEDLINE]
14.

Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.

Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF.

J Neurosci. 2002 Mar 1;22(5):1592-9.

PMID:
11880489
[PubMed - indexed for MEDLINE]
Free Article
15.

HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism.

Seong IS, Ivanova E, Lee JM, Choo YS, Fossale E, Anderson M, Gusella JF, Laramie JM, Myers RH, Lesort M, MacDonald ME.

Hum Mol Genet. 2005 Oct 1;14(19):2871-80. Epub 2005 Aug 22.

PMID:
16115812
[PubMed - indexed for MEDLINE]
Free Article
16.

Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice.

Stack EC, Smith KM, Ryu H, Cormier K, Chen M, Hagerty SW, Del Signore SJ, Cudkowicz ME, Friedlander RM, Ferrante RJ.

Biochim Biophys Acta. 2006 Mar;1762(3):373-80. Epub 2005 Dec 5.

PMID:
16364609
[PubMed - indexed for MEDLINE]
Free Article
17.

Huntington's disease: pathogenesis to animal models.

Kumar P, Kalonia H, Kumar A.

Pharmacol Rep. 2010 Jan-Feb;62(1):1-14. Review.

PMID:
20360611
[PubMed - indexed for MEDLINE]
Free Article
18.

Transcriptional dysregulation of coding and non-coding genes in cellular models of Huntington's disease.

Bithell A, Johnson R, Buckley NJ.

Biochem Soc Trans. 2009 Dec;37(Pt 6):1270-5. doi: 10.1042/BST0371270. Review.

PMID:
19909260
[PubMed - indexed for MEDLINE]
19.

Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.

Weydt P, Pineda VV, Torrence AE, Libby RT, Satterfield TF, Lazarowski ER, Gilbert ML, Morton GJ, Bammler TK, Strand AD, Cui L, Beyer RP, Easley CN, Smith AC, Krainc D, Luquet S, Sweet IR, Schwartz MW, La Spada AR.

Cell Metab. 2006 Nov;4(5):349-62. Epub 2006 Oct 19.

PMID:
17055784
[PubMed - indexed for MEDLINE]
Free Article
20.

The molecular biology of Huntington's disease.

Ho LW, Carmichael J, Swartz J, Wyttenbach A, Rankin J, Rubinsztein DC.

Psychol Med. 2001 Jan;31(1):3-14. Review.

PMID:
11200958
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk